326 related articles for article (PubMed ID: 30641037)
21. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
Muntané G; Dalfó E; Martinez A; Ferrer I
Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
[TBL] [Abstract][Full Text] [Related]
22. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
23. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Gu PS; Moon M; Choi JG; Oh MS
J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
[TBL] [Abstract][Full Text] [Related]
24. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
25. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
[TBL] [Abstract][Full Text] [Related]
27. Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology.
Gratuze M; Julien J; Petry FR; Morin F; Planel E
Sci Rep; 2017 Apr; 7():46359. PubMed ID: 28402338
[TBL] [Abstract][Full Text] [Related]
28. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.
Schultz MK; Gentzel R; Usenovic M; Gretzula C; Ware C; Parmentier-Batteur S; Schachter JB; Zariwala HA
Neurobiol Dis; 2018 Oct; 118():161-176. PubMed ID: 30049665
[TBL] [Abstract][Full Text] [Related]
30. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.
Wills J; Jones J; Haggerty T; Duka V; Joyce JN; Sidhu A
Exp Neurol; 2010 Sep; 225(1):210-8. PubMed ID: 20599975
[TBL] [Abstract][Full Text] [Related]
31. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
32. Impaired burrowing is the most prominent behavioral deficit of aging htau mice.
Geiszler PC; Barron MR; Pardon MC
Neuroscience; 2016 Aug; 329():98-111. PubMed ID: 27167086
[TBL] [Abstract][Full Text] [Related]
33. Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model.
Ferrer I; Andrés-Benito P; Ausín K; Cartas-Cejudo P; Lachén-Montes M; Del Rio JA; Fernández-Irigoyen J; Santamaría E
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742871
[TBL] [Abstract][Full Text] [Related]
34. Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau.
Stoyka LE; Mahoney CL; Thrasher DR; Russell DL; Cook AK; Harris AT; Narayanan A; Janado TP; Standaert DG; Roberson ED; Volpicelli-Daley LA
eNeuro; 2021; 8(3):. PubMed ID: 33972291
[TBL] [Abstract][Full Text] [Related]
35. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.
Maeda S; Djukic B; Taneja P; Yu GQ; Lo I; Davis A; Craft R; Guo W; Wang X; Kim D; Ponnusamy R; Gill TM; Masliah E; Mucke L
EMBO Rep; 2016 Apr; 17(4):530-51. PubMed ID: 26931567
[TBL] [Abstract][Full Text] [Related]
36. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.
Duka T; Duka V; Joyce JN; Sidhu A
FASEB J; 2009 Sep; 23(9):2820-30. PubMed ID: 19369384
[TBL] [Abstract][Full Text] [Related]
37. Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model.
Green C; Sydow A; Vogel S; Anglada-Huguet M; Wiedermann D; Mandelkow E; Mandelkow EM; Hoehn M
Mol Neurodegener; 2019 Mar; 14(1):13. PubMed ID: 30917861
[TBL] [Abstract][Full Text] [Related]
38. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
39. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
40. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy.
Singh B; Covelo A; Martell-Martínez H; Nanclares C; Sherman MA; Okematti E; Meints J; Teravskis PJ; Gallardo C; Savonenko AV; Benneyworth MA; Lesné SE; Liao D; Araque A; Lee MK
Acta Neuropathol; 2019 Oct; 138(4):551-574. PubMed ID: 31168644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
